Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425879 | 0.92 | USP2 (0.38) | SMN1; SMN2USP2NR1H2ADORA1HPGD | |
| SCHEMBL13957491 | 0.92 | ADORA1 (0.39) | SMN1; SMN2USP2NR1H2ADORA1HPGD | |
| SCHEMBL428115 | 0.91 | ADORA1 (0.39) | SMN1; SMN2USP2NR1H2ADORA1HPGD | |
| SCHEMBL24940831 | 0.88 | USP2 (0.41) | SMN1; SMN2USP2NR1H2ADORA1HPGD | |
| SCHEMBL24940829 | 0.84 | USP2 (0.38) | SMN1; SMN2USP2ADORA1TSHRRORC | |
| SCHEMBL23390397 | 0.84 | USP2 (0.39) | SMN1; SMN2USP2NR1H2ADORA1HPGD | |
| SCHEMBL2206945 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2USP2NR1H2ADORA1HPGD | |
| SCHEMBL25245654 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2USP2NR1H2ADORA1HPGD | |
| SCHEMBL2793182 | 0.84 | ADORA1 (0.40) | SMN1; SMN2USP2NR1H2ADORA1HPGD | |
| SCHEMBL3629291 | 0.83 | NR1H2 (0.40) | SMN1; SMN2USP2NR1H2ADORA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2024263753-A1 | SULFOXIMINE BASED STT3A/B MODULATORS FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230026696-A1 | TRPV4 RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-26 | — | — | US | disclosed |
| US-20230026696-A1 | TRPV4 RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-26 | — | — | US | disclosed |
| US-11466013-B2 | ERK inhibitor and use thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-10-11 | — | — | US | disclosed |
| EP-4061124-A1 | TRPV4 RECEPTOR LIGANDS | University of Utah Research Foundation (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-115052478-A | TRPV4 receptor ligands | 犹他大学研究基金会 | 2022-09-13 | — | — | CN | disclosed |
| CN-113924292-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3911644-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | SMN1; SMN2 4817/4885USP2 2798/4885NR1H2 4027/4885 |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | SMN1; SMN2 3099/4885USP2 1176/4885NR1H2 945/4885 |
| US-20230026696-A1 | TRPV4 RECEPTOR LIGANDS | TRPV4, TRPV2, TRPV3 | SMN1; SMN2 4557/4885USP2 4576/4885NR1H2 231/4885 |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | UGT2B7, CYP3A7, STS | SMN1; SMN2 1493/4885USP2 3629/4885NR1H2 514/4885 |
| US-11466013-B2 | ERK inhibitor and use thereof | MAPK1, MAPK4, MAPK7 | SMN1; SMN2 4016/4885USP2 2931/4885NR1H2 683/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | SMN1; SMN2 3099/4885USP2 1176/4885NR1H2 945/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | SMN1; SMN2 4817/4885USP2 2798/4885NR1H2 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.